MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases

Annals of Surgery

Volumn 257, Issue 6, 2013, Pages 1089-1095

  Isella, Claudio ^a,d   Mellano, Alfredo ^b   Galimi, Francesco ^c   Petti, Consalvo ^a   Capussotti, Lorenzo ^e   Simone, Michele De ^b   Bertotti, Andrea ^b,d   Medico, Enzo ^a,d   Muratore, Andrea ^b  

^a IRC at C   (Italy)

^b Department of Surgical Oncology ^*  (Italy)

^c CANDIOLO CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e MAURIZIANO HOSPITAL   (Italy)

Author keywords

Biomarker; Cancer recurrence; Colorectal cancer; Liver metastasis; MACC1; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; IRINOTECAN; MESSENGER RNA; METASTASIS ASSOCIATED IN COLON CANCER 1; OXALIPLATIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; COLORECTAL CANCER; FEMALE; FOLLOW UP; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; HUMAN; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE METASTASIS; MALE; METASTASIS RESECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REGIONAL METASTASIS;

AGED; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DIAGNOSTIC IMAGING; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; LIVER NEOPLASMS; MALE; MONTE CARLO METHOD; MUTATION; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RAS PROTEINS; RNA, MESSENGER; ROC CURVE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879103342     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31828f96bc     Document Type: Article

References (50)

1. Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer. 2002;38:1023-1033.
2. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715-722, discussion 722-724.
3. Capussotti L, Muratore A. Neoadjuvant chemotherapy and resection of advanced synchronous livermetastases before treatment of the colorectal primary. Br J Surg. 2006;93:872-878; author reply 1564.
4. Muratore A, Ribero D, Zimmitti G, et al. Resection margin and recurrencefree survival after liver resection of colorectal metastases. Ann Surg Oncol. 2010;17:1324-1329.
5. Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20:985-992.
6. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26:4906-4911.
7. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-1016.
8. Sorbye H, Mauer M, Gruenberger T, et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg. 2012;255:534-539.
9. Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999;189:291-299.
10. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318; discussion 318-321.
11. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996;77:1254-1262.
12. Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg. 2007;246:183-191.
13. Reissfelder C, Rahbari NN, Koch M, et al. Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol. 2009;16:3279-3288.
14. Maithel SK, G̈onen M, Ito H, et al. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery. 2012;151:162-170.
15. Boardman LA. Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer. Genome Med. 2009;1:36.
16. Shirahata A, Shinmura K, Kitamura Y, et al. MACC1 as a marker for advanced colorectal carcinoma. Anticancer Res. 2010;30:2689-2692.
17. Arlt F, Stein U. Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol. 2009;41:2356-2359.
18. Stein U, Dahlmann M, Walther W. MACC1-more than metastasis? Facts and predictions about a novel gene. J Mol Med (Berl). 2010;88:11-18.
19. Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009;15:59-67.
20. Shimokawa H, Uramoto H, Onitsuka T, et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg. 2011;141:895-898.
21. Chundong G, Uramoto H, Onitsuka T, et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res. 2011;31:1141-1145.
22. Shirahata A, Fan W, Sakuraba K, et al. MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res. 2011;31:777-780.
23. Qiu J, Huang P, Liu Q, et al. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011;9:166.
24. Qu JH, Chang XJ, Lu YY, et al. Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2012;18:2995-3003.
25. Shirahata A, Sakata M, Kitamura Y, et al. MACC 1 as a marker for peritonealdisseminated gastric carcinoma. Anticancer Res. 2010;30:3441-3444.
26. Zhang R, Shi H, Chen Z, et al. Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells. J Exp Clin Cancer Res. 2011;30:83.
27. Zhang RT, Shi HR, Huang HL, et al. Expressions of MACC1, HGF, and C-met protein in epithelial ovarian cancer and their significance [in Chinese]. Nan Fang Yi Ke Da Xue Xue Bao. 2011;31:1551-1555.
28. Stein U, Smith J, Walther W, et al. MACC1 controls Met: what a difference an Sp1 site makes. Cell Cycle. 2009;8:2467-2469.
29. Migliore C, Martin V, Leoni VP, et al. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res. 2012;18(3):737-747.
30. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
31. Capussotti L, Muratore A, Mulas MM, et al. Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg. 2006;93:1001-1006.
32. Galimi F, Torti D, Sassi F, et al. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res. 2011;17:3146-3156.
33. Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts ("Xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508-523.
34. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
35. Therneau T. A Package for Survival Analysis in S. R package version 2.37-4. 2013. http://CRAN. R-project.org/package=survival.
36. Sing T, Sander O, Beerenwinkel N, et al. ROCR: Visualizing the performance of scoring classifiers. R package version 1.0-4. 2009. http://CRAN. Rproject.org/package=ROCR.
37. Isella C, Renzulli T, Cora D, et al. Mulcom: a multiple comparison statistical test for microarray data in Bioconductor. Bmc Bioinformatics. 2011;12:382.
38. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29:1261-1270.
39. Deschoolmeester V, Boeckx C, Baay M, et al. KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolutionmelting analysis. Br J Cancer. 2010;103:1627-1636.
40. Rothenberg SM, Mohapatra G, Rivera MN, et al. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 2010;70:2158-2164.
41. Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009;15:7322-7329.
42. Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012;18:2257-2268.
43. Farĩna Sarasqueta A, Zeestraten EC, Van Wezel T, et al. PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell Oncol (Dordr). 2011;34:523-531.
44. Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011;17:1122-1130.
45. O'Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010;28:3937-3944.
46. Nash GM, Gimbel M, Shia J, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010;17:572-578.
47. Zhang Y, Wang Z, Chen M, et al. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer. 2012;11:23.
48. Pichorner A, Sack U, Kobelt D, et al. In vivo imaging of colorectal cancer growth and metastasis by targeting MACC1 with shRNA in xenografted mice. Clin Exp Metastasis. 2012;29:573-583.
49. Wang N, Xie JM, Zheng DY, et al. Establishment of BGC-823/pBaBb-puro- MACC1 gastric cancer cell line stably expressing MACC1 and its tumorrelated gene expression profiles [in Chinese]. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32:312-316.
50. Ercolani G, Cucchetti A, Cescon M, et al. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. Eur J Cancer. 2011;47:2291-2298.